Background: Relapse after allogeneic hematopoietic stem cell transplantation (AlloHSCT) for Ph+ve acute lymphoblastic leukemia (Ph+ ALL) remains the major cause of treatment failure. Use of tyrosine kinase inhibitors (TKIs) for post-transplant maintenance is not well defined. Methods: Database search using PubMed, Cochrane library, and Embase was performed on 08/10/2017 yielding 861 articles, 17 articles met inclusion criteria (n = 502). Results: Patients in seven prospective trials (n = 224) received imatinib post-transplant (PT) either prophylactically or pre-emptively for median duration of 3-12 months, at dose of 200–600 mg. Imatinib yielded a better overall survival (OS) (1.7 to 5-year OS was 30-86.7%), disease free survival (DFS) (30–81.5%) and low relapse rate (13 – 31.5%). Chen et al, in 2012 reported 52.4% higher OS (p = 0.0) with imatinib. Five retrospective trial patients (n = 221) received TKI PT either prophylactically or pre-emptively for median duration of 1-11 months, at dose of 300–800mg. TKI prophylactically led to better OS (1-year OS-100%, 2-year OS-66.7%), DFS (20-100%) and with the 3-year relapse rate of 63.6%. Three prospective trial patients (n = 28) received nilotinib PT prophylactically for a median duration of 0-20 month, at dose of 200-300 mg. Nilotinib prophylactically had a better OS (2-year OS was 69%, and mOS was 35.5 months) and DFS (56% in one study and median 34.1 months in another). Two retrospective trial patients (n = 29) received post-AlloHSCT dasatinib for median duration of 11-15 months, at dose of 50-100 mg. Patients who received dasatinib had a better OS (3-year 87% in one study, and median OS was 22 months in another study) and DFS (88%). Conclusions: Post-transplant prophylactic or maintenance TKIs in Ph+ ALL showed increase in OS, DFS and decrease in relapse rates. Limited data appears to favor a prophylactic rather than a pre-emptive strategy. In retrospective trials, use of dasatinib reported increase 3-year OS-87% whereas imatinib 3-year OS was 40% is post-transplant patients. The second generation TKIs have better outcomes in comparison to imatinib although further studies are needed to assess this fact definitively.